Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
Phase 2
Active, not recruiting
NCT03954236
| Condition | Non-sclerotic Cutaneous Chronic Graft-versus-host Disease |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 24 participants |
|---|
| Interventions | topical ruxolitinib 1.5% cream, Topical vehicle/moisturizer cream |
|---|
| Start date | May 14, 2019 |
|---|
| Completion date | Feb 6, 2027 |
|---|
| Results posted | Feb 10, 2026 |
|---|
Summary
The purpose of this study is to compare the safety and effects of ruxolitinib 1.5% cream with those of standard moisturizers in people with non-sclerotic chronic cutaneous GVHD.
Reduction in Body Surface Area (BSA) From Day 1 and Day 28
28 days (+/-3 days) · % of body surface area
| Experimental: Participants With Graft-versus-host Disease (GVHD) | 14.4 ± 0.003 % of body surface area |
|---|
| Experimental: Participants With Graft-versus-host Disease (GVHD) | 6.2 ± 0.003 % of body surface area |
|---|
| Experimental: Participants With Graft-versus-host Disease (GVHD) | 14.5 ± 0.003 % of body surface area |
|---|
| Experimental: Participants With Graft-versus-host Disease (GVHD) | 10.4 ± 0.003 % of body surface area |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.